《Box the Pox: 降低天花和其他正痘病毒的风险》

  • 来源专题:新发突发传染病
  • 发布时间:2024-03-09
  • WASHINGTON, D.C. (Feb. 20, 2024) – Despite the global eradication of smallpox more than 40 years ago, the Bipartisan Commission on Biodefense reports smallpox and other orthopoxviruses remain a significant threat to public health and today released a new plan with nine actionable recommendations for the Administration and Congress to significantly mitigate the biological risk to our Nation and the world.

    Just this month, epidemiologists at the Alaska Department of Health reported the first known fatal case of Alaskapox, a novel orthopoxvirus first identified in 2015. Box the Pox: Reducing the Risk of Smallpox and Other Orthopoxviruses (click the title to view the report) details how Alaskapox, smallpox, and other orthopoxviruses pose significant risks due to their potential for weaponization, accidental release, and vulnerability of populations who stopped routinely vaccinating against smallpox in the 1970s.

    “With a mortality rate of thirty percent, the traditional global strategy of reacting to biological events after they begin is not viable for a disease like smallpox. The impact of a third of the population perishing within two to three weeks would be catastrophic for society, national security, and the global economy,” said former U.S. Senate Majority Leader, Commissioner Tom Daschle. “There is no benefit in waiting and every reason to act now. By implementing the nine recommendations in our new plan, we can ensure the continued elimination of smallpox and address the threat of diseases caused by orthopoxviruses preemptively.”

    Experts who have spoken with the Commission worry that the current contents of the U.S. Strategic National Stockpile to combat smallpox are depleted or expired, with not nearly enough vaccine, antivirals, and other medical countermeasures to deal with the consequences of an attack with this disease.

    “Should a smallpox attack occur, we would need to immunize within 7 days for the vaccines to be effective,” said former Michigan Congressman and former Chairman of the House of Representatives Committee on Energy and Commerce, Commissioner Fred Upton. “There wouldn’t be enough time to manufacture, procure, distribute, and deliver enough smallpox vaccines, antivirals, and diagnostic tests to protect our Nation or prevent the disease from spreading. This Commission urges the Administration and Congress to reassess the contents of the Stockpile and ensure that they are commensurate with today’s threats.”

    Additionally, the Commission’s plan details why the Intelligence Community (IC) must reinvigorate its efforts to produce biological intelligence. Over the years since the United States ceased its own biological weapons program, the IC reduced its emphasis on the biological weapons threat. Today, however, the threat has never been greater. The growth of synthetic biology also means that even non-state actors could have the capacity to produce smallpox. The Commission recommends that the Central Intelligence Agency identify activities occurring in foreign laboratories involved in biological weapons research and determine the physical disposition of previously weaponized smallpox produced by the Former Soviet Union, among other intelligence actions. The Commission also recommends that the Department of Defense makes sure U.S. and allied military forces can fight and win in areas biologically contaminated with smallpox. This is no time to depend on old personal protective equipment and filters that wear out in days or weeks.

相关报告
  • 《美国FDA关于降低血液和血液成分传播寨卡病毒风险的修订建议》

    • 来源专题:新发突发疾病防治
    • 发布时间:2018-07-10
    • 美国食品和药物管理局(FDA)7月6日宣布,它已经修订了针对寨卡病毒捐献血液和血液制品的测试指南,允许使用FDA许可的测试对该捐赠进行汇总测试。 修订后的指南取代了2016年8月的指南,该指南建议对在美国及其领土上捐赠的各个血液单位进行核酸检测。该更新表示,汇总的测试方法将有助于降低寨卡病毒传播的风险,除非在特定地理位置增加当地蚊媒病毒的风险,这将触发该地区个人捐赠测试的回归。作为另一种选择,FDA表示血液机构可以使用经批准的病原体减少装置用于血浆和某些血小板产品。 该公告是在FDA的血液制品咨询委员会于2017年12月提出的建议之后发布的,该委员会审议了科学证据,并与其他公共卫生机构进行了磋商。 美国食品和药物管理局生物制品评估和研究中心主任,医学博士,医学博士Peter Marks表示,鉴于寨卡病例减少,该机构正在逐步测试个人捐赠。 “这通常更具成本效益,减少了血液设施的负担。但是,FDA将继续密切监测情况,并酌情重新考虑维持血液供应安全所需的措施。” 5月,在美国研究寨卡捐献血液筛查的研究人员发现,这个过程出乎意料地花费了很多,而且很少发现。根据该研究,增强的测试成本为4200万美元,并且发现了9个正面捐赠。 然而,研究人员表示,退出当前的测试建议是一项复杂的决定,因为科学家们仍在整理寨卡相关的血液供应问题和输血相关感染的风险。 同样在5月,FDA批准了罗氏分子诊断公司(Roche Molecular Diagnostics)进行的cobas测试的另一项索赔,允许该测试用于筛选针对寨卡病毒的汇集血液和血浆捐赠。
  • 《2019 新型冠状病毒疫情进展和风险评估 》

    • 来源专题:新发突发疾病(新型冠状病毒肺炎)
    • 发布时间:2020-02-03
    • 根据溯源调查和检测结果、发病情况以及对新型冠状病毒的认知,目前认为 2019 新型冠状病毒源于野生动物,但具体动物还不清楚。虽然病毒从动物到人的溢出和完成适应性变异过程是否发生在武汉华南海鲜批发市场尚需进一步证实,但武汉华南海鲜批发市场是疫情早期病例的主要感染来源地。截至 1 月 27 日 24 时,国家卫生健康委收到内地 30 个省(区、市)累计报告确诊病例 4515 例,现有重症病例 976 例,累计死亡病例 106 例;累计收到港澳台地区通报确诊病例:香港特别行政区 8 例,澳门特别行政区 7例,台湾地区 5 例。截至 1 月 26 日,10 个国家通报确诊病例:泰国 7 例,日本 3 例,韩国 3 例,美国 3 例,越南 2 例,新加坡 4 例,马来西亚 3 例,尼泊尔 1 例,法国 3 例,澳大利亚 4 例。 中国各级政府均采取强有力的防控措施,高频的媒体沟通和交流提高公众的防病意识,通过停止大型集会、戴口罩、减少私人聚会等方式减少感染机会,采用手机定位回溯、旅行和亲友来访调查等多种形式促进病例的早发现和管理、降低进一步传播机会,做好医院感染控制、预防院内感染。武汉城市公交、地铁、轮渡、长途客运暂停运营;无特殊原因,市民不离开武汉;机场、火车站离汉通道暂时关闭。湖北省其他 12 个地市也都相继启动不同程度的公共交通管制。 2019 新型冠状病毒从进入人群传播至今 1 个多月,尚处于社区传播的早期阶段。本期风险评估结论与上期相同,即:随着中国政府强有力防控措施的落实,有望使疫情围堵工作达到预期的防控效果,避免疫情发生更大规模的流行乃至大流行。